We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Barinthus Biotherapeutics PLC Sponsored ADR been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Barinthus Biotherapeutics PLC Sponsored ADR is a member of the Medical sector. This group includes 918 individual stocks and currently holds a Zacks Sector Rank of #10. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Barinthus Biotherapeutics PLC Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for BRNS' full-year earnings has moved 34.5% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, BRNS has gained about 8.4% so far this year. In comparison, Medical companies have returned an average of 4.4%. This means that Barinthus Biotherapeutics PLC Sponsored ADR is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, Agilent Technologies (A - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 10.9%.
For Agilent Technologies, the consensus EPS estimate for the current year has increased 3.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Barinthus Biotherapeutics PLC Sponsored ADR is a member of the Medical - Biomedical and Genetics industry, which includes 439 individual companies and currently sits at #163 in the Zacks Industry Rank. On average, this group has gained an average of 10.1% so far this year, meaning that BRNS is slightly underperforming its industry in terms of year-to-date returns.
On the other hand, Agilent Technologies belongs to the Medical - Products industry. This 86-stock industry is currently ranked #92. The industry has moved -17.3% year to date.
Investors with an interest in Medical stocks should continue to track Barinthus Biotherapeutics PLC Sponsored ADR and Agilent Technologies. These stocks will be looking to continue their solid performance.
View the Zacks #1 Rank List
Image: Bigstock
Is Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Barinthus Biotherapeutics PLC Sponsored ADR been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Barinthus Biotherapeutics PLC Sponsored ADR is a member of the Medical sector. This group includes 918 individual stocks and currently holds a Zacks Sector Rank of #10. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Barinthus Biotherapeutics PLC Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for BRNS' full-year earnings has moved 34.5% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, BRNS has gained about 8.4% so far this year. In comparison, Medical companies have returned an average of 4.4%. This means that Barinthus Biotherapeutics PLC Sponsored ADR is performing better than its sector in terms of year-to-date returns.
Another stock in the Medical sector, Agilent Technologies (A - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 10.9%.
For Agilent Technologies, the consensus EPS estimate for the current year has increased 3.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Barinthus Biotherapeutics PLC Sponsored ADR is a member of the Medical - Biomedical and Genetics industry, which includes 439 individual companies and currently sits at #163 in the Zacks Industry Rank. On average, this group has gained an average of 10.1% so far this year, meaning that BRNS is slightly underperforming its industry in terms of year-to-date returns.
On the other hand, Agilent Technologies belongs to the Medical - Products industry. This 86-stock industry is currently ranked #92. The industry has moved -17.3% year to date.
Investors with an interest in Medical stocks should continue to track Barinthus Biotherapeutics PLC Sponsored ADR and Agilent Technologies. These stocks will be looking to continue their solid performance.